SpyBiotech

Executive Summary

SpyBiotech is a clinical-stage biotechnology company based in Oxford, UK, leveraging its proprietary SpyTag/SpyCatcher protein 'superglue' technology to develop novel vaccines targeting infectious diseases, cancer, and chronic conditions. Founded in 2017, the company's platform enables rapid and precise assembly of antigens onto delivery vehicles such as virus-like particles (VLPs) and viral vectors, offering versatility for pandemic preparedness and personalized medicine. SpyBiotech is currently in Phase 1 clinical trials, evaluating its lead vaccine candidate for safety and immunogenicity. The technology has attracted interest from academic and industry partners due to its potential to accelerate vaccine development and improve efficacy. While still in early stages, the company's strong IP portfolio and experienced management team position it well for future growth. However, risks include clinical trial outcomes, manufacturing scalability, and competition from other vaccine platforms. Overall, SpyBiotech represents a promising play in next-generation vaccine technology.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data readout for lead vaccine candidate75% success
• Q4 2026Strategic partnership or licensing deal with a major pharmaceutical company60% success
• Q2 2026Completion of preclinical proof-of-concept studies for oncology vaccine program80% success